-- Earnings Flash (EQ) EQUILLIUM Reports Q1 Loss $-1.17
4:03PM ET 5/12/2022 MT Newswires...
Quotes Snapshot > EQ
Equillium Inc EQ:NASDAQ
Last Price$2.47Cboe Real-Time Last Sale as of 11:59AM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.06(2.37%)
Bid (Size)$2.44 (100)
Ask (Size)$2.56 (100)
Day Low / High$2.47 - 2.60
Volume18.3 K
Read more news Recent News
HC Wainwright Adjusts Equillium's Price Target to $15 From $12, Reiterates Buy Rating
7:36AM ET 3/24/2022 MT NewswiresEquillium (EQ) has an average rating of buy and price targets ranging from $12 to $15, according to analysts polled by Capital IQ. (MT Newswires covers...
Equillium Starts Phase 3 Study of Itolizumab for Treatment of Acute Graft-Versus-Host Disease
8:28AM ET 3/04/2022 MT NewswiresEquillium (EQ) said Friday it has launched a phase 3 trial of itolizumab in patients with acute graft-versus-host disease, a multi-system disorder caused...
View all Commentary and Analysis
Equillium (EQ) Investor Presentation - Slideshow
2:50PM ET 12/13/2021 Seeking AlphaEquillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)
11:30AM ET 10/08/2021 Seeking AlphaCompany Profile
Business DescriptionEquillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA. View company web site for more details
| Address | 2223 Avenida de la Playa La Jolla, California 92037 |
| Phone | +1.858.240.1200 |
| Number of Employees | 11 |
| Recent SEC Filing | 05/12/2022 8-K |
| President, Chief Executive Officer & Director | Bruce D. Steel |
| Chief Operating Officer & Senior Vice President | Christine Zedelmayer |
| Chief Financial Officer | Jason A. Keyes |
| Director & Chief Scientific Officer | Stephen Connelly |
Company Highlights
| Price Open | $2.58 |
| Previous Close | $2.53 |
| 52 Week Range | $2.12 - 7.75 |
| Market Capitalization | $84.7 M |
| Shares Outstanding | 34.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.36 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -48.97% |
Analyst Ratings as of 05/13/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |